Peptide blends: GLOW, KLOW, Wolverine
GLOW, KLOW and Wolverine are marketing names for vials that mix two, three or four peptides — and no blend has any regulatory standing in the US. Three of the four components (BPC-157, TB-500, KPV) were recommended by the FDA’s advisory committee on July 23, 2026, each for a single named indication; the fourth (GHK-Cu) is not due for review until early 2027. Those votes are advisory, cover single substances, and change nothing about a blend. What is sold under these names is gray-market material outside the regulated supply.
What the names mean
Three names recur in peptide forums and clinic menus. GLOW is GHK-Cu, BPC-157 and TB-500 in one vial. KLOW is the same three with KPV added — the K is the addition. Wolverine is the simplest: BPC-157 and TB-500. Each is sold as a single lyophilized vial at a fixed ratio, labeled “for research use only”, under a name chosen to promise something — skin, recovery, healing. In GLOW and KLOW the copper peptide GHK-Cu makes up most of the vial by weight, which matters for what follows: it is the one component the FDA has not yet looked at.
Four components, four separate statuses
The blends are assembled from substances that each sit at a different point in the FDA’s process, and none of those points is “authorized”.
BPC-157 was recommended for the 503A bulks list on July 23, 2026, 8–6 with one abstention, for ulcerative colitis — not for tendon, joint or skin repair, which is what the blends are sold for. TB-500 was recommended the same day, by the same margin, for wound healing. KPV likewise, for wound healing and inflammatory conditions. All three recommendations are advisory; the FDA decides whether to open rulemaking, and as of September 2026 it has not. GHK-Cu was not on the July agenda at all. Injectable GHK-Cu is in the second batch the committee is due to review before the end of February 2027; until then it has not even had its hearing. All four were removed from 503A Category 2 in April 2026 because their nominations were withdrawn — a procedural step, not a safety finding — and none is on Category 1. In plain terms: no approved product, no bulks-list entry, no lawful compounding, for any of them, today.
Why a blend has no path — even after a favorable vote
The July votes are widely reported as “peptides approved”. Walk through what they actually were and the blends fall out of the picture at every step. The committee voted substance by substance, against the specific indication each nominator proposed. A bulks-list entry, if the FDA ever finalizes one, is likewise per substance. It would allow a state-licensed 503A pharmacy to compound that substance for an individual patient, on a prescription, where a prescriber documents a clinical need. Nobody nominated “glow”, “recovery” or “anti-aging”, and the committee heard no evidence on any combination. A pharmacy could in principle combine listed substances in a patient-specific preparation — but only substances that are listed, and GHK-Cu, the bulk of GLOW and KLOW, will not have been considered before 2027, let alone listed. So the earliest any single component could lawfully be compounded is 2027, if the FDA acts at all; a four-peptide “KLOW” from a licensed pharmacy is on no timeline anyone can point to.
What is actually being sold
Because no lawful supply exists, everything sold under these names is gray-market synthesis: no prescription, no licensed pharmacy, no verified identity, purity or sterility. Blends compound the problem. A purity figure on a certificate says what fraction of a vial is peptide; it does not say which peptide, or whether four are present in the stated ratio. ECRI and ISMP, reviewing analytic testing of gray-market peptide products in April 2026, reported purity ranging from 5% to 75% of label, with arsenic and lead above the thresholds accepted for injectable drugs. The white paper does not identify who performed that testing — a limitation worth carrying alongside the number. Clinics that advertise KLOW as something they “prescribe” are dispensing a product with no regulatory basis, whatever the setting. This site does not link to, compare or evaluate sellers of any of these vials.
Why this page sits on a regulatory tracker
The blends are the retail face of the substances the FDA is reviewing. Their names do the marketing work that the evidence has not done, and they package a committee’s narrow, advisory, per-substance votes into a single vial that implies the opposite. Our status board tracks each substance on its own terms.
Is KLOW legal in the US?+
Did the July 2026 vote make GLOW or KLOW legal?+
Could a compounding pharmacy make GLOW or KLOW after rulemaking?+
Is the GHK-Cu in these vials the GHK-Cu the FDA will review?+
What is the difference between GLOW, KLOW and Wolverine?+
Primary sources: FDA Pharmacy Compounding Advisory Committee meeting of July 23–24, 2026 (docket FDA-2025-N-6895) and reported vote tallies · Federal Register notice of April 16, 2026 (July agenda and second-batch list) · FDA notice of April 15, 2026 removing the nominated peptides from 503A Category 2 · section 503A of the FD&C Act · ECRI and ISMP, “White Paper on Compounded Peptide Products” (© April 2026, announced 5 May 2026), which reports the purity range without naming the testing laboratory. Blend compositions are as marketed by research-chemical vendors; by policy this site does not link to or evaluate sellers.
Medical & editorial disclaimer. This article is independent reference information, not medical advice and not a recommendation to use any substance. None of the peptides discussed here is FDA-approved, and none may lawfully be compounded today. Nothing here should be used to obtain, prepare, or self-administer any substance. Talk to a licensed clinician about your health. Peptide Docket is not affiliated with the FDA and does not sell peptides.